Sichuan University National Engineering Research Center for Biomaterials
published a 2026 regulatory-science paper proposing a progressive strategy for pre-market immunological evaluation of recombinant collagen medical devices, co-authored with device manufacturers including Gempharmatech, Jiangsu Trautec Medical Technology and Shanghai LabEx Biotech.
- Country
- China
regulatory-science
cn
Coverage
| CN | EU | US | |
|---|---|---|---|
| fibers-textiles | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Recombinant collagen & gelatin | fibers-textiles | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.